期刊文献+

腹腔镜辅助治疗胃癌与传统开腹术的临床疗效分析 被引量:3

Clinical analysis of laparoscopy-assisted surgery and open surgery for gastric cancer
下载PDF
导出
摘要 目的:观察腹腔镜手术治疗胃癌与传统开腹术的临床疗效。方法:抽取54例行胃癌手术的患者进行研究,按照手术方式分为腹腔镜组与开腹组,每组27例。对比两组的术中指标(手术时间、出血量、切口长度、肿瘤距切缘距离及淋巴结清扫数)及术后指标(排气时间、下床活动时间、住院时间)。结果:腹腔镜组与开腹组相比较手术时间长,但是出血量少,切口长度小,排气、下床活动及住院时间短,两组比较差异有统计学意义(P<0.05);肿瘤距切缘距离及淋巴结清扫数两组比较差异无统计学意义(P>0.05)。结论:腹腔镜应用于胃癌治疗,减少了手术创伤,疗效满意。同时仍需要提高手术操作技术,减少手术时间。 Objective:To observe the clinical effect of laparoscopic gastric cancer surgery and open surgery. Method:54 patients with gastric cancer operation were selected as the subjects. The patients were divided into laparoscopy group and laparotomy group, 27 cases in each group, two groups of patients with operative time, intraoperative blood loss, wound length, incision and distance of the tumor, the number of lymph node cleaning ,exhaust time, ambulation time and hospitalization time were observed. Results:The intraoperative blood loss, wound length ,exhaust time, ambulation time and hospitalization time were significantly lower than the laparotomy group,but the operation time was longer than the aparotomy group, and there was significant difference (P〈 0.05) .There was no significant difference in incision and distance of the tumor, the number of lymph node cleaning between two groups(P〉 0.05 ) .Conclusion:Laparoscopy-assisted approach for the gastric cancer treatment could reduce the trauma to patients. The improvement of the operation skills can reduce the operation time.
出处 《安徽卫生职业技术学院学报》 2017年第6期22-23,共2页 Journal of Anhui Health Vocational & Technical College
基金 国家自然科学青年基金(编号:81602803)
关键词 腹腔镜 胃癌 开腹手术 临床疗效 Laparoscopy Gastric cancer Open surgery Clinical efficacy
  • 相关文献

参考文献5

二级参考文献78

  • 1郑成竹,胡兵.腹腔镜胃癌根治术淋巴结清扫的若干问题[J].中国实用外科杂志,2005,25(10):592-593. 被引量:23
  • 2蔡秀军,张宇华.腹腔镜胃癌根治术现状与展望[J].中国微创外科杂志,2006,6(2):84-86. 被引量:32
  • 3周平红,姚礼庆,徐美东,陈巍峰,钟芸诗,高卫东,何国杰,秦新裕.内镜黏膜下剥离术治疗直肠类癌[J].中华胃肠外科杂志,2007,10(4):319-322. 被引量:37
  • 4Dong B,Zhu YM.Molecular-targeted therapy for cancer.Chin J Cancer,2010,29(3):340-345.
  • 5Scaltriti M,Baselga J.The epidermal growth factor receptor pathway:a model for targeted therapy.Clin Cancer Res,2006,12(18):5268-5272.
  • 6Wainberg ZA,Anghel A,Desai AJ,et al.Lapatinib,a dual ECFR and HER2 kinase inhibitor,selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.Clin Cancer Res,2010,16(5):1509-1519.
  • 7Pinto C,Di Fabio F,Siena S,et al.Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).Ann Oncol,2007,18 (3):510-517.
  • 8Patel D,Bassi R,Hooper A,et al.Antiepidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 het-erodimerization and activation.Int J Oncol,2009,34(1):25-32.
  • 9Liu ZM,Liu LN,Li M,et al.Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer.Oncol Rep,2009,22(3):515-520.
  • 10Agus DB,Gordon MS,Taylor C,et al.Phase clinical study of pertu-zumab,a novel HER dimerization inhibitor,in patients with advanced cancer.J Clin Oncol,2005,23(11):2534-2543.

共引文献24

同被引文献21

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部